Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,047.54 -23.01 (-0.45%) Dow
38,324.96 -178.73 (-0.46%) Nasdaq
15,641.29 -55.35 (-0.35%) Bitcoin USD
64,692.98 -2,088.50 (-3.13%) CMC Crypto 200
1,391.67 -32.43 (-2.28%)
Corcept Therapeutics Incorporated (CORT)
| Previous close | 23.00 |
| Open | 23.00 |
| Bid | 22.07 x 100 |
| Ask | 22.21 x 100 |
| Day's range | 22.05 - 23.28 |
| 52-week range | 20.84 - 34.28 |
| Volume | |
| Avg. volume | 1,190,456 |
| Market cap | 2.299B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 23.55 |
| EPS (TTM) | 0.94 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 42.73 |
ZacksCorcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.
GlobeNewswireCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
MENLO PARK, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced positive results from the open-label portion of the pivotal Phase 3 GRACE trial of its proprietary selective cortisol modulator relacorilant in patients with all etio
ZacksCorcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
